WellSpan Health announces a platform-wide expansion of its Hippocratic AI partnership, with voice agent 'Ana' now managing over 160,000 patient calls and 7,000 hours of conversation monthly — expanding from appointment scheduling into post-discharge follow-ups, chronic disease management, and clinical triage co-development.
On July 30, 2026, WellSpan Health — a Pennsylvania-based integrated health system — announced a major expansion of its partnership with Hippocratic AI, transforming what began as individual use-case deployments into a platform-wide commitment spanning inbound, outbound, ambulatory, and inpatient settings. The generative AI voice agent 'Ana,' developed jointly by WellSpan and Hippocratic AI, now handles over 160,000 patient calls and 7,000 hours of conversation per month — making it one of the largest verified deployments of clinical voice AI in a U.S. health system.
The expansion adds three new dimensions to the partnership. First, Ana is moving beyond its initial role in inbound call answering and primary care scheduling to conduct post-discharge follow-ups, chronic disease check-ins, and proactive outreach to patients who have missed imaging appointments — closing care gaps that historically required manual phone outreach by clinical staff. Second, WellSpan becomes one of the first U.S. health systems to formally co-develop next-generation regulated clinical AI with Hippocratic AI, including trials of voice AI for clinical triage tasks and the launch of the 'Hippocratic AI Orchestrator' to help care teams navigate patient care plans and health histories. Third, a dedicated team of clinical, engineering, and deployment specialists from Hippocratic AI will be embedded onsite at WellSpan's York, Pennsylvania campus for real-time design, deployment, and refinement of voice AI workflows.
The scale of the deployment provides real-world evidence for voice AI's operational impact in healthcare. Ana supports multilingual conversations — currently Spanish, with Haitian Creole and Nepali planned — and can switch languages fluidly mid-conversation. Every new Ana use case follows a structured governance framework with clinician oversight, full conversation transcripts available for review, and the ability to live-transfer to human clinicians when the AI encounters situations beyond its scope. WellSpan President and CEO Roxanna Gapstur described the expansion as an investment in 'access, care team support, and personalized patient experience,' while Hippocratic AI co-founder and CEO Munjal Shah characterized the next phase as moving from scarcity to 'abundance' — reimagining care delivery without the constraint of limited human clinician bandwidth.
The partnership has been running for nearly two years, with Ana initially focused on colorectal cancer screening outreach before expanding into broader inbound call management. The July 2026 expansion positions WellSpan as an operational blueprint for what platform-wide voice AI deployment looks like in a health system — a model that other provider organizations are watching closely. For the broader voice AI industry, the WellSpan-Hippocratic partnership demonstrates that clinical voice AI has moved decisively from pilot to production: 160,000 calls per month is not a proof-of-concept — it is a core operational system that patients depend on for their healthcare. As Hippocratic AI's Polaris Voice system also recently secured FDA 510(k) clearance for clinical patient interaction (April 2026), the company is now positioned at the intersection of regulatory approval and real-world scale — a combination that few competitors in the healthcare voice AI space have achieved.
